Amarin Corp PLC (AMRN) 옵션

Sure enough ... So far there is nothing to get excited about unless you are looking to short a pullup to falling resistance (ice line and 200 day moving average).
As I wrote before, "There is way too much overhead to blast through on less than average volume."
Current chart confirms the former:


By the way, here is a chart that displays the prognostic value of volume interaction with trendlines or overhead resistance.



y'all should do yourselves a favor and memorize this valuable information. It could be very profitable if you were to ever follow this basic TA 101 principle,

Chuck, I think the Supreme Court is about to be extremely busy. My guess is that section 8 Hatch Waxman issues aren't going to make the cut. Under normal circumstances they might have heard this case. Not sure how I view that.
Sleven,

FlyFishingStocks

I thought we were going to flow with the market ? Today not so much !!

Michael

Cool we are on the same page. Thank you for all you do for the board.

https://www.courtlistener.com/docket/18701895/amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/
Sleven,

https://www.courtlistener.com/docket/59859757/dr-reddys-laboratories-inc-v-amarin-pharma-inc/?page=2
Sleven,

Chuck, I am aware. I followed the suit. I have no opinion about the chances of the court taking the case. The decision by the appeals court was unanimous in Amarin v Hikma. GSK v Teva had a scathing descent.
Sleven,

Should be OTC..

@Number sleven
Teva tried the same thing with the supreme court against GSK. Result denied.

https://www.scotusblog.com/case-files/cases/teva-pharmaceuticals-usa-inc-v-glaxosmithkline-llc/

RMB, I cannot get a V script, so I use EPA-only fish oil (Carlson Elite EPA). I take 4gms per day, and only with meals. My EPA level is at 7.16%, which is off the charts. So it seems that meals shouldn't inhibit much of the absorption. And I consume a lot of fiber as well.

I think the what the article is missing is a more in depth discussion about size and constituents of the meal. A humungous meal may definitely impede absorption of V to some degree. The other big thing for me (and I don't recall it being discussed in the article) is soluble fiber. Some fat ingested along with V will help with absorption but significant amounts of soluble fiber could really mess up absorption.

IMO, The Supreme's are far too busy and not interested in taking up a case that has not yet been adjudicated. They'll let this play out.

Good Question. I've been on VASCEPA for over a decade. I usually take my morning dose without breakfast. About a year ago my blood draw measured AA, EPA and DHA (6.40, 4.30, 1.90). I need to get my AA down, but my EPA is good.

Invite available to add.
https://www.amarincorp.com/investor-relations/events-and-presentations

https://www.nasdaq.com/press-release/amarin-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference

Sleven, you are right that the district case wouldn't "stop", as a rule. But most likely, Hikma would request an extension on that case in order for them to prepare for the SC case. And I can't see a reason that the district court wouldn't grant it.

Although I think it's a slim chance that the SC takes the case.

There is no FAFO going on in Spain!

They are dead serious (pun intended) in reducing the prevalence of CVD in Spain and $AMRN is a part of that consortium.

“We have appeared before the Health Commission to present the Report of Proposals for improvement and call for institutional and legislative action in the approach to CVD in Spain that we have carried out with a committee of 22 Experts, 18 collaborators and supported by 8 pharmaceutical companies”

I wish there was public data on how VAZKEPA® is being Rx’d in Spain/Portugal like in the UK. Maybe we’ll get some color on this in the upcoming CC.

https://www.linkedin.com/posts/bioinnova-consulting_saludcardiovascular-pulsovital-alianzacardiovascular-ugcPost-7297642420291137536-njKC?utm_source=social_share_send&utm_medium=member_desktop_web&rcm=ACoAAAdDmycBzT_CwLIulyFqANe8SLMF4KH2Odo

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Is vascepa more effective on an empty stomach?
https://www.drugchatter.com/chat/55270/is-vascepa-more-effective-on-an-empty-stomach/

Probability Assessment:

The Supreme Court typically grants certiorari to fewer than 2% of petitions. However, cases involving regulatory and patent law conflicts, especially those affecting a major industry like pharmaceuticals, have a higher chance of review.
https://cdn.patentlyo.com/media/2025/02/Petition-for-Certiorari-Hikma-v-Amarin.pdf?_gl=1*v102w1*_ga*MTY5NDcwOTk5MC4xNzI1MTA4ODUw*_ga_G57FX3W4N3*MTczOTk1Nzg5MC44LjEuMTczOTk1Nzk3OC4wLjAuMA

Unfortunately the descimation came through the courts.  Not directly, because if we would have only lost the Marine indication scripts, our stock price would be double digits, but the door got opened and the characters (Generics, insurers, pharmacies) got to work. 

Sleven, very true I did not read the filing and very true I have a very strong opinion about how these patent cases progress through the courts. I have never seen it to be a bone of contention that a primary strategy of the infringer is to use the courts to stretch out the process as long and far as possible. I have also been involved in complex litigation cases (as an investor) and have first hand knowledge of how the various court cases directly or indirectly impact their respective schedules. My only points today are 1- there is a very slim statistical chance that the higher court will take up the case and 2- the way the system is, just going through this step after the appellate ruling adds time to the whole process. I think you will see first hand that Delaware will be impacted (perhaps slightly) . Most likely, Hickma did not spend the large resources needed to achieve a 1% chance of victory. They get a little more. Again, it all adds to the time.

I understand your desire to mitigate your investment risk and applaud your research discipline. I learned years ago after reading countless briefs, opinions, Markman rulings, etc,etc that I don't have the training to be an effective patent attorney or even play one at home. I truly believe that any value I will realize from this investment will not come through the courts. Cheers !

RMB, Good for you. You read the filing.
Sleven,

I got a real kick out of this:

"Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug labeling ruling that it says will “effectively vitiate” a common practice that helps bring more low-cost medications to market."


Yeah they want to continue infringing on legally obtained and valid patents.  "A common practice" - meaning that everyone who can, does it.  The whole system is working to cheat and steal. Be it the mfgrs, insurers, PBMs, or pharmacies.  And they are really admitting it in the statement by saying it brings more low cost drugs to market. Sure if they were confined to the VHTG indication they would be selling a lot less GV. 

Skipper, Back to the beginning of our conversation. It sounds like what you are saying is, I didn't read the filing, but I have strong opinions about it.
Sleven,

https://stocktwits.com/SanDiegoLiving/message/604724136

https://stocktwits.com/SanDiegoLiving/message/604721917

https://stocktwits.com/SanDiegoLiving/message/604708943

Skipper, That is inaccurate. You also didn't respond to my question.
Sleven,

I can only go by previous experience.If this case is taken by the Supreme Court, Delaware will slow or stop. Not by mandate but by practical deference to extremely busy court schedules.

Skipper, If the case is taken by the high court, it doesn't stop the forward movement at the district level. Not until the Supreme Court makes a ruling in favor of Hikma. The decision by the appeals court holds until a new decision is issued. Did you read the the filing? This could backfire on Hikma.
Sleven,

Sleven, both sides and the DE judge knew this filing would show up when it did (always the final minutes of the final due date) so the delay is inherent in the process. The lower court will keep an eye on it and if by some chance it is taken up by the Supreme Court, the DE case will come to a halt. Also, you will most likely see requests for delays by Hickma throughout the delivery schedule in the Delaware court until this matter is fully addressed.

Rose, If AMRN does a reverse split without
either a share buyback nor additional shares
bought by Sarissa, would be very concerning
and indicate a need for all of AMRN's sequestered
cash. I do hope that Sarissa increases its stake
as that would demonstrate confidence in AMRN's
future.

Skipper, Since the filing with the Supreme Court doesn't delay the case, what is your point?
Sleven,

JRoon, to add further confusion see below explanation for an accelerated filer.

https://www.sec.gov/resources-small-businesses/capital-raising-building-blocks/sec-filer-status-reporting-status

no chance (extremely thin

My bad. The request would be for a filing by the Solicitor General.
Sleven,

Kick them again:

Hikma takes Amarin's 'skinny label' fight to the Supreme CourtAlexis KramerPharma Editor
Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug labeling ruling that it says will “effectively vitiate” a common practice that helps bring more low-cost medications to market.

If we actually are now sitting around speculating as to when by law this mess of a company must reluctantly share with its owners the most basic of information regarding its ongoing operations, then perhaps its time to put a true "Jersey" end to this relationship. Wonder if there is enough in petty cash to charter a bus on a one-way company trip to the Meadowlands? I have full birthrights to such dark humor.

Lizzy, Thank you.
Sleven,

Lizzy, actually, I think Amarin is an "Accelerated Filer", and has 75 days. At least, that's how they have filed in the past.

I've found conflicting information online about filing requirements, but I checked how they filed each of their 10K's and Q's, and they are an Accelerated Filer. So I guess March 15~ish would be the date.

But they've always filed by March 1st in the past.

EDIT: Lizzy, actually, it appears that they have filed as a "Large" accelerated filer in the past, and then switched recently to "Accelerated Filer" (probably because their market cap dropped so much). Which is why they used to always file by March 1st.

Sad to say AMRN's market cap is less than cash on hand! Maybe they haven't confirmed their earnings date because of the recent changes in CEO & CFO?? Just sayin
Since it's the responsibility of the CEO to sign off on audited financials, it may be more complicated than in the past because of the expansion of the EU and other countries. Plus the CFO is on the line as well.

JRoon, see below.

Yes, Amarin Pharma is currently considered a small cap company. As of February 2025, Amarin's market cap is approximately $222.53 million.

Since Amarin qualifies as a smaller reporting company, it has 90 days from the end of its fiscal year to file its 10-K with the SEC. Given that their fiscal year ends on December 31, they would need to file their 10-K by March 31, 2026.

JRoon, I'll check what's considered small cap.

I am hoping for good news at the Q4 C.C....Perhaps an authorized generic of Vascepa will be seriously discussed.... Perhaps Lr Et EPA will be discussed.

Lizzy, I thought the cutoff for small company earnings was smaller than Amarin ($75 Million?).

JRoon, Amarin has 90 days from year end to file 10K as it's considered a small cap company. Then if they still don't have the 10K signed off by the CEO they can file for a 15 day extension.

Sleven, it's just a one page notice of a telephone call btw Apotex and Amarin that lasted 1 hr and 5 minutes! No further info.

Amarin must release earnings by February 28th (day 60 is a Saturday), so they have 10 days.

In the past, they have always pre-announced results, usually within 2 weeks after the end of the year (last year they announced results on January 10th). They did not do that this year. Not sure if that is good news or bad news. I am hoping they are making some significant announcements on the ER CC, and thus wanted to wait and release everything at the same time at the CC. I'm a bit surprised that they have not at least announced a date for the CC yet. Last year, they announced the earnings call on February 15th.

Last year, they also wrote a letter to shareholders on January 22nd. They did not do that this year.

We will see.

https://www.courtlistener.com/docket/59859757/dr-reddys-laboratories-inc-v-amarin-pharma-inc/?page=2
Sleven,

Nuke, The petition was well written. The lawyers for Hikma really didn't like the precedent that was set by the ruling. (Matter of fact not law). In the conclusion they requested that the court request an opinion from the Attorney General.
Sleven,

Sorry, Mr Crouch, you can't have it both ways. Either the Generics infringed or they didn't? Hikma infringed... come on admit it!!!